BAHA Osseointegrated denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for baha osseointegrated are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies BAHA (Bone-Anchored Hearing Aid) as Experimental

A "experimental or investigational" denial means Cigna has determined that the evidence base for the procedure or device does not yet meet its coverage standard — typically that the technology is safe and effective based on well-designed clinical studies and recognized by applicable medical specialty organizations. For BAHA osseointegrated devices, this denial is uncommon for FDA-approved devices used in their cleared indications, but may arise when: (1) a new device generation or bilateral implantation pattern has not yet been evaluated under Cigna's technology-assessment cycle, (2) the patient's specific hearing-loss subtype falls outside the device's cleared indication, or (3) the surgical approach proposed deviates from standard technique.

## Why This Denial Is Appealable

FDA-cleared BAHA devices used within their cleared indications have an established evidentiary basis. Multiple major audiology and otolaryngology professional societies have published position statements supporting BAHA for appropriate candidates. If the denial classifies a cleared, guideline-supported device as experimental, it is factually contestable. The appeal should present the FDA-clearance documentation, the device's cleared indication, and the endorsement of the applicable professional guideline organizations.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 require full-and-fair internal review, including the right to submit medical literature and expert opinion. File within the deadline on the denial letter.
• External review: After a final internal denial, an accredited IRO conducts an independent review using current evidence standards. The window is generally approximately four months. Experimental-device denials are among the most commonly reversed by IROs when FDA clearance is documented.
• Expedited review: Request if delay is causing ongoing significant functional impairment.

## Documentation to Gather

1. FDA-clearance documentation — the 510(k) clearance summary or PMA approval letter for the specific BAHA device model, confirming the cleared indication and patient population. 2. Device labeling (IFU) — the FDA-approved Instructions for Use listing cleared indications and clinical criteria. 3. Audiological and otolaryngological evaluation — current audiogram, word-recognition scores, and surgeon/audiologist letter confirming the patient falls within the cleared indication. 4. Professional society support — reference to position statements or clinical practice guidelines from the applicable otolaryngology and audiology professional organizations (cite the organization, not specific statistics). 5. Clinical-outcomes documentation — any peer-reviewed systematic reviews or technology assessments in the published literature supporting BAHA efficacy (submit the publications; do not quote statistics in the appeal letter itself).

## Criteria-Mapping Structure

Obtain Cigna's published technology-assessment or coverage policy for BAHA. Identify each evidentiary criterion Cigna applies. For each, map the FDA-clearance document, the IFU cleared indication, and the relevant guideline organization's position to the criterion. Present this as a structured table showing that the device meets Cigna's own stated evidence standard.